Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24917022 | 1.00 | TMPRSS2 (0.53) | TMPRSS2GSK3BHTTNCOA1NCOA3 | |
| SCHEMBL24789430 | 0.95 | TMPRSS2 (0.54) | TMPRSS2TSHR | |
| SCHEMBL25439354 | 0.95 | TMPRSS2 (0.54) | TMPRSS2TSHR | |
| SCHEMBL25913451 | 0.93 | TMPRSS2 (0.52) | TMPRSS2GSK3BHTTNCOA1NCOA3 | |
| SCHEMBL24791743 | 0.93 | TMPRSS2 (0.52) | TMPRSS2GSK3BHTTNCOA1NCOA3 | |
| SCHEMBL24791733 | 0.92 | TMPRSS2 (0.52) | TMPRSS2GSK3BHTTNCOA1NCOA3 | |
| SCHEMBL24917248 | 0.90 | TMPRSS2 (0.50) | TMPRSS2GSK3BHTTNCOA1NCOA3 | |
| SCHEMBL25913453 | 0.90 | TMPRSS2 (0.50) | TMPRSS2GSK3BHTTNCOA1NCOA3 | |
| SCHEMBL25909967 | 0.90 | TMPRSS2 (0.57) | TMPRSS2GSK3BHTTNCOA1NCOA3 | |
| SCHEMBL25382387 | 0.90 | TMPRSS2 (0.51) | TMPRSS2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885GSK3B 3317/4885HTT 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.